BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  Phase 2 Study Initiated to Evaluate Jaguar Health’s Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

  December 19, 2024

   · 

  6 min read
• Press Releases

  Breckenridge announces final FDA approval for Methadone Hydrochloride Multi-Dose Injection

  December 19, 2024

   · 

  2 min read
• Press Releases

  NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  December 19, 2024

   · 

  1 min read
• Press Releases

  AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  December 19, 2024

   · 

  1 min read
• Press Releases

  Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

  December 19, 2024

   · 

  3 min read
• Press Releases

  Colorado’s Life Sciences Ecosystem Raised $2.15 Billion in 2024

  Fundraising Exceeds $2B for the Second Time in Four-Year Period

  December 19, 2024

   · 

  1 min read
• Press Releases

  NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics

  December 19, 2024

   · 

  3 min read
• Press Releases

  Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

  December 19, 2024

   · 

  7 min read
• Press Releases

  Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

  December 19, 2024

   · 

  5 min read
• Press Releases

  Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

  December 19, 2024

   · 

  7 min read